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Characterization of a novel murine Sost ERT2 Cre model
targeting osteocytes
Delphine B. Maurel1,7, Tsutomu Matsumoto2, Julian A. Vallejo1, Mark L. Johnson1, Sarah L. Dallas1, Yukiko Kitase2, Marco Brotto3,
Michael J. Wacker4, Marie A. Harris5, Stephen E. Harris5 and Lynda F. Bonewald 1,2,6
Transgenic mice are widely used to delete or overexpress genes in a cell specific manner to advance knowledge of bone biology,
function and disease. While numerous Cre models exist to target gene recombination in osteoblasts and osteoclasts, few target
osteocytes specifically, particularly mature osteocytes. Our goal was to create a spatial and temporal conditional Cre model using
tamoxifen to induce Cre activity in mature osteocytes using a Bac construct containing the 5’ and 3’ regions of the Sost gene (Sost
ERT2 Cre). Four founder lines were crossed with the Ai9 Cre reporter mice. One founder line showed high and specific activity in
mature osteocytes. Bones and organs were imaged and fluorescent signal quantitated. While no activity was observed in 2 day old
pups, by 2 months of age some osteocytes were positive as osteocyte Cre activity became spontaneous or ‘leaky’ with age. The
percentage of positive osteocytes increased following tamoxifen injection, especially in males, with 43% to 95% positive cells
compared to 19% to 32% in females. No signal was observed in any bone surface cell, bone marrow, nor in muscle with or without
tamoxifen injection. No spontaneous signal was observed in any other organ. However, with tamoxifen injection, a few positive
cells were observed in kidney, eye, lung, heart and brain. All other organs, 28 in total, were negative with tamoxifen injection.
However, with age, a muscle phenotype was apparent in the Sost-ERT2 Cre mice. Therefore, although this mouse model may be
useful for targeting gene deletion or expression to mature osteocytes, the muscle phenotype may restrict the use of this model to
specific applications and should be considered when interpreting data.
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INTRODUCTION
The osteocyte was thought to be a passive cell, but in the last
decade it has been shown to have many functions, such as
regulation of bone formation and resorption, generation of
endocrine factors that target kidney and muscle and mechan-
otransduction (reviewed in1). Today it is accepted that the
osteocyte, the most abundant cell in bone, is a key player in
bone regulation and adaptation to loading or unloading.2,3 Based
on recent research, new drugs are being developed such as anti-
sclerostin antibody that appears promising in animal models4 and
is now being tested in humans.5 Other factors made by
osteocytes, which are the focus for therapeutics, are RANKL6 and
FGF23.7
In contrast to osteoblasts and osteoclasts, there are very few Cre
animal models targeting osteocytes specifically.8–11 The first
osteocyte-selective cis regulatory region used to target osteocytes
and late osteoblasts was Dentin Matrix Protein-1 (Dmp1) based on
the studies of Yang and colleagues on the 10, 8, and 2.5 kb
promoter regions.12 The Dmp1-Cre mouse model was developed
by these same investigators using the 10 kb fragment of the
Dmp1 promoter (−9 624-+ 4 439).13 Cre activity was determined
using a Rosa26R reporter mouse in which LacZ expression is
activated following excision of a stop cassette. Reporter expres-
sion was mainly observed in osteocytes with low expression in
osteoblasts. However, when this mouse was crossed with the Ai9
mouse in which the recombination event causes activation of
tdTomato fluorescent protein (Jackson Labs), fluorescence was
detected in several other tissues including muscle, brain, kidney,
and the majority of osteoblasts on the bone surface.9,10 Gorski and
colleagues found that the Cre recombination in muscle was
dependent on the animal.14 Unintended targeting of Dmp1-Cre
showed an effect on the gastrointestinal mesenchyme.15 It is not
clear why this variability in Cre activation occurs but it may be due
to mouse strain and/or spontaneous activation during various
stages of development.
Other attempts have been made to produce a more osteocyte
specific Cre mouse model using the 8 kb Dmp1 promoter.16
However, in this mouse, Cre activity was observed on endocortical
and cancellous surfaces of bone.9 To avoid non-specific activity of
Dmp1-Cre in developmental stages, a tamoxifen-inducible Cre was
generated in which a mutated estrogen ligand-binding domain
was used.17 In this mouse model, some spontaneous (non-
tamoxifen induced) Cre activity was observed in osteocytes, but
not in osteoblasts. Low tamoxifen targeted mainly osteocytes
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while high tamoxifen levels also activated Cre in osteoblasts.9 No
activity was observed in muscle, perhaps because of no expression
during developmental stages.
Other osteocyte selective markers in addition to Dmp1 have
been identified, including Phex, E11/gp38, Mepe, FGF23, and
Sost.1 Dmp1, Phex, and E11 are mainly expressed in early
osteocytes while Mepe, FGF23, and Sost are expressed in mature
osteocytes. Sclerostin is a secreted cysteine−knot protein among
the DAN family, and is encoded by the Sost gene.18 It was
discovered in 2001 while studying a mutation that caused the
disease sclerosteosis, where family members had massive bone
overgrowth. Sost mRNA is expressed in many tissues during
embryogenesis in humans, including heart, aorta, liver and
kidney.18–20 In the adult, it has been reported only in terminally
differentiated cells encased in a mineralized matrix, osteocytes,
hypertrophic chondrocytes and cementocytes.21–24
Recently a Sost-Cre has been generated which leads to
recombination in osteocytes but not osteoblasts or lining cells.25
However, large numbers of fluorescent cells are present in bone
marrow and some osteoclasts are positive, suggesting that Cre
recombination occurred during development in hematopoeitic
precursor cells. As there is a critical need for additional osteocyte
selective Cre models, we focused on creating a new Cre ERT2
model, driven by the Sost promoter. Our hypothesis was that Sost
ERT2 Cre would be expressed only in mature osteocytes in bone
and not in other tissues and therefore would be useful for future
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Fig. 1 Generation of Sost ERT2 Cre mice. a A Sost Bac construct containing the 5’ and 3’ regions of the Sost gene (Sost ERT2 cre) was made, using
RP24-178J4 BAC (157Kb) with the Sost gene. Recombineering was used to replace the ATG region with the CreERT2 frt-kan-frt cassette, and the
frt-kan-frt cassette was then removed with I-arabinose inducible flip recombinase in the SW105 bacteria. The digest with EcoRV shows a 11.6 kb
band that is only 0.9 kb after insertion of the CreERt2-frt-kan-frt cassette, using the 5’ probe(purple). After removing the kan cassete the EcoRV
band goes from 14.2 kb to 12.7 kb with the 3’ probe (bottom right of 1 a). b Representative images from the four founder lines (#1, #2, #3, #4)
that were crossed with Ai9 tdTomato mice to analyze the DNA recombination in osteocytes after tamoxifen injection (300–555mg·kg−1).
Images of the femur were taken at 20x magnification. The upper panels are brightfield images and the lower panels show TdTomato
fluorescence. Scale bar represents 100 µm. Line #2 appeared the most promising and osteocyte specific as compared to the other lines
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research targeting osteocyte expression and functions. Here we
describe this new Cre mouse model for targeting osteocytes.
RESULTS
Generation of Sost ERT2 mice
Sost-ERT2 cre mice were generated in order to create a spatial and
temporal conditional Cre model using tamoxifen to induce Cre
activity in osteocytes. This has been done by using the Sost Bac
construct containing the 5’ and 3’ regions of the Sost gene (Sost
ERT2 cre). Using RP24-178J4 BAC (157Kb) with the Sost gene,
recombineering was used to replace the ATG region with the
CreERT2 cassette, and the frt-neo-frt cassette was then removed
with L-arabinose inducible flip recombinase. (Fig. 1a). Founder
lines on a C57Bl6 background were created by pronuclear
injection of the SostBAC-CreERT2 construct. These lines are viable
and fertile. Four founder lines (Line #1, #2, #3 and #4) were then
crossed with the Rosa26-loxP-stop-loxP-tdTomato or Ai9 allele
(B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J reporter mouse to
analyze activity of the Cre transgene in bone in the presence
and absence of tamoxifen and to determine any off target activity
of the Cre transgene.
Cre activity in bone following tamoxifen injection
Out of the four transgenic lines, only line #2 showed strong and
consistent Cre recombination in osteocytes following tamoxifen
treatment (Fig. 1b). Line #1 and line #4 showed few positive
osteocytes as did line #3, which also showed off target activity in
other tissues/cells. Therefore, strain #2 was selected for further
characterization.
Cre activity in bone using Line #2
In bone, as determined using the Sost Cre-ERT2 tdTomato reporter
mouse, Cre was expressed specifically in osteocytes after
tamoxifen injection. In the Cre+ mice, fluorescence was only
observed in osteocytes (Fig. 1b Line #2 and Fig. 2a) with no
fluorescence in osteoblasts, osteoclasts, bone marrow or muscle.
Expression in femurs with tamoxifen injection in 2 mo old females
was (15.3 ± 6.3)% (n= 4), in 2 mo old males was (52 ± 2)% (n= 2),
in 5 mo old females it was (28.0 ± 7.4)% (n= 4) and (40.5 ± 17.8)%
in 5 mo old males (n= 4). Occasionally a very few chondrocytes
were positive in adult mice (data not shown). It has
been described previously that hypertrophic chondrocytes can
express sclerostin.22 The osteocyte lacuno-canalicular network
could also be visualized in these mice using confocal microscopy
(Fig. 2b, c).
Spontaneous Cre activity in the absence of tamoxifen injection
Surprisingly, a background level of spontaneous Cre activation
was observed without tamoxifen injection in Sost Cre-ERT2
tdTomato mice at 2 and 5 mo of age. Because of this finding, 2
day old and one mo old mice were also examined to determine
when this spontaneous (“leaky”) activity started. No fluorescence
was observed in bones or in any soft tissues without tamoxifen at
2 days of age (Fig. 3a). Tail vertebrae were then examined in 1 and
2 mo old Sost Cre-ERT2 tdTomato mice at baseline and after
tamoxifen injection. In females, the percentage of positive
osteocytes was approximately 6% at 1 mo and increased to
around 12% at 2 mo of age. In males, the ‘leakiness’ was about 2%
at 1 mo compared to about 31% at 2 mo of age. No fluorescence
was ever observed in Cre– mice.
Tamoxifen injection increased Cre activity
The spontaneous Cre activity did not appear to increase
significantly after 2 months of age in tail vertebra (Table 1). One
month after tamoxifen injection of 2 mo old or 5 mo old Cre+
mice, the percentage of Cre expressing osteocytes was increased
in females and in males compared to vehicle control injected
animals (Fig. 3 and Table 1). Tamoxifen appeared to double the
number of positive osteocytes (Table 1). It was interesting that Cre
recombination was observed more extensively in males than in
females, which is consistent with the expression of Sost in
bone.26,27 There was also variability in the amount of Cre activity
between littermates as one unusual animal had an 86%
expression at 5 months before the injection of tamoxifen (Fig. 3b,
c). Both the baseline (without tamoxifen) and inducible (with
tamoxifen) Cre activity in bone was highly specific to osteocytes,
with no Cre activity in osteoblasts, bone marrow or muscle.
A small amount of off target Cre activity was observed in non-
bone tissues
To determine the specificity of Cre activity and identify any off
target activity in the Sost Cre-ERT2 tdTomato model, the tdTomato
fluorescence was examined in an extensive set of 27 different soft
tissues. No signal was observed in any of the soft tissues in any
Cre– mice nor in the Cre+ mice without tamoxifen (data not
shown). Off target effects were only observed in Cre+ mice
injected with tamoxifen. With tamoxifen injection, fluorescence
200 µm 50 µm 10 µm
a b c
Fig. 2 Specificity of Cre activity in osteocytes and dendritic processes in Sost ERT2 Cre mice. In bone, the tdTomato signal showed strong
specificity for osteocytes in Sost ERT2 Cre/tdTomato mice treated with tamoxifen, as no signal was seen in osteoblasts, muscle or bone marrow.
a Epifluorescence microscopy in the femur at 4x magnification. Higher power b (20 × ) and c (100 × ) confocal images are shown of the
lacunocanalicular network in the femur of these mice showing specific targeting of Cre activity to osteocytes and also showing that these
mice may be useful to analyze the osteocyte network as well as their dendrites and connections. TdTomato is shown in red and DAPI signal is
in blue
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was detected in a very small percentage of cells in the eye, kidney,
heart, lung and brain (Fig. 4a). All the other tissues analyzed were
negative for Cre activity (Table in Fig. 4b). In lung and heart, the
signal appeared to localize with blood vessels. Some cells in the
glomerulus were positive in kidney, and the retina and choroid in
the eye. A very small and specific region of the brain was positive.
We also performed immunostaining for sclerostin in these tissues
but signal was only detectable in osteocytes (data not shown) and
not in the other tissues even those with Cre activity as indicated
by the tdTomato reporter.
Bone and muscle phenotype in Sost-CreERT2 mice in the absence
of floxed gene recombination
We next examined the Sost-CreERT2 mice without crossing them
with reporter lines or floxed lines to determine whether there
were any effects of the Sost-CreERT2 transgene. At 6 months of
age no visible, external differences could be observed between
wildtype Cre− and Sost-CreERT2 male and female mice, nor
significant visible differences in muscle mass or bone mass by x-
ray (Fig. 5). There were also no significant differences in body
weight between Cre− and Sost-CreERT2 in males or females at 1,
3, or 6 mo of age nor were there any significant differences in
bone parameters except in trabecular thickness in males
where the Sost-CreERT2 were significantly wider than the Cre−
(Table 2).
In 1 and 3 month old males, SOL, EDL, and gastrocnemius
muscles from Sost-Cre− ERT2 were heavier than wildtype controls
(in mg): 1 mo SOL 6.1 ± 1.4 vs. 4.5 ± 0.3; 1 mo EDL 6.1 ± 0.8 vs. 5.2
± 0.3; 1 mo gast. 99.1 ± 20.6 vs. 75.4 ± 2.1; 3 mo SOL 12.3 ± 1.1 vs.
8.9 ± 1.2; 3 mo EDL 12.2 ± 1.2 vs. 10.6 ± 1.0; 3 mo gast. 200.2 ± 22.4
vs. 155.2 ± 11.0 (P < 0.05; n= 6 for all muscles). Interestingly, in
1 month old females, SOL and gastrocnemius muscle weighed less
in Sost-CreERT2 compared to wildtype controls (in mg): SOL 4.5 ±
0.2 vs. 5.5 ± 0.5; gast. 68.0 ± 9.7 vs. 83.1 ± 4.2 (P < 0.05; n= 4–6)
with no difference in EDL, 5.3 ± 0.1 vs. 5.5 ± 0.3 (P > 0.05; n= 4). At
3 months of age, there was no significant difference in female
muscle weights: SOL 7.9 ± 1.9 vs. 6.9 ± 0.4; EDL 9.9 ± 2.7 vs. 7.9 ±
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Fig. 3 Examples of spontaneous Cre activity in some osteocytes with age and induction of more osteocyte-specific Cre activity with
tamoxifen. a Brightfield, DAPI and TdTomato images of the femur in 2 day old Sost ERT2 Cre/tdTomato mice without tamoxifen treatment at 4x
and 20x magnifications show no spontaneous Cre activity. b Percentage of positive osteocytes in tail vertebrae in single animals at 2 mo
before injection of tamoxifen (Baseline) and at 3 months of age after tamoxifen injection (Tam+ 1mol·L−1) and at 5 mo before injection of
tamoxifen and 6 mo of age after tamoxifen injection is shown. The 3–5th caudal tail vertebra in females and males in Cre– control mice, Cre+
injected with vehicle, Cre+ injected with tamoxifen are shown. Some spontaneous induction of Cre activity occurs in the absence of
tamoxifen. Cre-mediated recombination was higher in males than in females. One 5 mo old male animal showed 86% baseline or
spontaneous Cre activity. c and d Images of the tdTomato fluorescent reporter to indicate Cre-mediated recombination in the tail vertebrae
of male and female Sost ERT2 Cre/tdTomato mice with and without tamoxifen treatment at baseline and 1 month after tamoxifen injection
(c. 2 mo and d. 5 mo). Cre– controls with vehicle injection are also shown. These images are from the same animals as shown in 3b. The
scalebars represent 100X
Table 1. Percent positive osteocytes in tail vertabrae in male and
female Cre+ mice with and without tamoxifen (250–550mg·kg−1)
injection. The basal Cre activity or ‘leakiness’ does not appear to
increase after 2 mo. (Mean plus/minus standard error)
Sex Age Basal Activity or
“leakiness”
With
Tamoxifen
Sample size
Female 2 mo 11.5 ± 6.4 25.0 ± 4.1 4
5 mo 13.0 ± 2.2 24.3+ 4.1 3
Male 2 mo 31 ± 8.3 74.3 ± 14.7 3
5 mo 31 ± 13.1 53.4 ± 7.6 4
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0.4; gast. 138.4 ± 26.3 vs. 119.7 ± 3.1 (P > 0.05; n= 6). By 6 mo of
age, the EDL and SOL from both female and male Sost-CreERT2
mice were significantly heavier than wildtype Cre− controls
(Fig. 6a).
Histological characterization of myosin fiber type in 6 month
old EDL and SOL of Sost Cre−ERT2 mice was performed by IHC
and H-E staining. The characteristic arrangement of muscle
fibers (i.e., polygonal shaped fibers, relatively small variation in
size, peripheral nuclei, and scant endomyosial collagen) was
disrupted in Sost-CreERT2 compared with control. The Sost-
CreERT2 muscles appeared myopathic, particularly in males. By
H&E staining, most of the muscle cellular nuclei in Sost-CreERT2
were centralized, and muscle fibers appeared more scattered,
rounded, and grouped with significantly more collagen
indicating fiber replacement by fibrosis; all key characteristics
of myopathy. Normally with myopathy, fibers show atrophy;
however, in this case, perhaps in adaptation to the overall
muscle hypertrophy, the muscle fibers are not atrophic,
particularly in the SOL muscle. (Fig. 6b). Also interesting was
that despite the myopathic features, the Sost-CreERT2 muscle
fibers did not show any splitting.
Moreover, our fiber typing by immunostaining suggests that in
both male and female Sost-CreERT2 EDL muscles, larger areas of
purple indicate a higher presence of MHC type I fibers and in the
male EDL compared to controls, areas of green were also noted,
indicating MHC Type IIa fibers. These changes would be expected
to contribute to reduced force generation based on the
presence of more slow-twitch (oxidative) fiber types, which have
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Fig. 4 Off target Cre activity only with tamoxifen injection of Sost ERT2 Cre/tdTomato mice. a Positive Cre activity in femoral bone for
comparison to off target expression in cells in the eye, lung, heart, brain and kidney. Males 2 mo old are shown for femur and heart and males
5 mo old are shown for eye, lung, brain, and kidney. Left panels show brightfield images and right panels show TdTomato fluorescence. Scale
bar represents 1 000 µm. b All the other organs and glands examined (22 in total) for off target Cre activity were negative
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slower speeds of contraction and thus overall lower force/power
outputs. A similar trend is also observed in the SOL muscles,
where in general there seems to be more MHC type I muscle fibers
in the Sost-CreERT2 muscles with the SOL male muscles
also displaying a few red MHC type IIb (fast twitch, glycolytic)
muscle fibers. While the few IIb could increase force output, very
likely the other structural changes, such as those indicating higher
amounts of collagen, might also account for the overall force
decrement.
Concerning muscle function, differences in absolute and
specific force produced at different frequencies of stimulation of
EDL and SOL muscles for 3 and 6 month old males and females
are shown in Fig. 7. As would be expected based on the
disruption in muscle histology, male Sost-CreERT2 EDL and SOL
display reduced specific force at submaximal and maximal
frequencies (from 20 to 130 Hz) at both 3 months (Fig. 7a) and
6 month (Fig. 7b) compared to Cre− controls. Females displayed
a reduction in specific force in Sost-CreERT2 SOL muscles at both
3 (Fig. 7a) and 6 months (Fig. 7b), and EDL specific force at
6 months, but not 3 months compared to Cre− controls. In terms
of absolute force, Sost-CreERT2 EDL muscles from males at 3 and
6 months displayed a decrease in absolute force compared to
Cre− controls, but there was no difference in SOL at either age.
Sost-CreERT2 EDL muscles from females at 3 months showed
increased force at submaximal frequencies, but at 6 months
there was no difference compared to Cre− controls. Female
Sost-CreERT2 SOL muscles at 3 months showed a decrease in
absolute force at maximal frequencies, but no change at
6 months compared to Cre− controls.
To determine at what age this muscle phenotype was occurring,
RNAseq was performed on gastrocnemius muscle since the EDL and
SOL were already being utilized for contractile studies. The
gastrocnemius is a mixed muscle type also located in the hindlimb
and therefore was a good muscle to reflect both fast and slow
twitch muscle fiber types. Since changes in the SOL and EDL muscle
force parameters were apparent earlier in males than females, the
time point selected for RNAseq were 1 mo old in males and 3 mo
old in females. Already at one month of age, highly significant
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Fig. 5 Images of 6 mo male/female intact, muscle, and X-ray plus table of micro CT results. Images of 6-month-old female and male mice, Cre–
control and Sost-CreERT2 /tdTomato mice w/wo skin. The x-ray images were of the same mouse. None of the mice had been injected with
tamoxifen.
Table 2. Micro CT analysis of trabecular bone and cortical bone in tibia and whole body weight. (n = 4–5)
Bone parameters Cre- Cre+ P value
Female Male Female Male Female Male
Trabecular bone analysis (Tb.BV/TV)/% 0.083 ± 0.013 0.088 ± 0.023 0.112 ± 0.031 0.127 ± 0.034 0.093 0.116
Tb.N/µm-1 1.773 ± 0.252 4.175 ± 0.473 2.406 ± 0.568 3.953 ± 0.366 0.052 0.487
Tb.Th/µm 0.045 ± 0.002 0.044 ± 0.002 0.045 ± 0.004 0.054 ± 0.006 0.843 *0.024
Tb.Sp/µm 0.438 ± 0.235 0.238 ± 0.030 0.389 ± 0.102 0.247 ± 0.026 0.678 0.676
Cortical bone analysis (Ct.BV/TV)/% 0.916 ± 0.003 0.915 ± 0.006 0.915 ± 0.004 0.915 ± 0.002 0.790 0.977
Ct.Th/µm 0.212 ± 0.002 0.211 ± 0.014 0.208 ± 0.003 0.210 ± 0.009 0.100 0.870
Body Weight Gram 31.70 ± 2.574 28.00 ± 3.317 31.75 ± 2.111 26.26 ± 2.353 0.977 0.367
No significant differences were observed between control Cre–, mice, compared to Sost-CreERT2 mice/tdTomato, of the same gender using unpaired Student’s
t-test *P < 0.05
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differences were observed in the muscle of male mice and few
differences in the 3 mo female mice compared to controls. (See
Fig. 1 supplemental data). In the 1mo male mice there were 1 857
2-fold upregulated genes and 1 959 downregulated genes, whereas
in 3 mo females there were 37 upregulated and 34 downregulated
genes (Supp Fig. 1A). Only 14 upregulated and 21 downregulated
genes overlapped between males and females. The overlapping
genes are shown in Supplementary Table 1 and Table 2. A pathway
analysis of the male gastrocnemius was performed showing that
inflammation mediated by chemokine and cytokine signaling
pathways was the major upregulated pathway in Cre+ as compared
to Cre– male mice (Supp. Figure 1B). The inflammatory related genes
upregulated in Cre+male mice are shown in Supplementary Table 3.
The Wnt signaling pathway was the major downregulated pathway
in the Cre+male muscle. The GEO accession number for the RNAseq
data is GSE119761.
Sost-CreERT2 Cre+ animals sacrificed at 10–12 mo of age had
larger muscles and less fat than controls (Fig. 8). In 12 mo old
females, a significant decrease in body size was observed in Cre+
mice compared to Cre− controls (Fig. 8).
DISCUSSION
As there is a critical need for additional osteocyte selective Cre
models, we generated a new Cre ERT2 model, driven by the Sost
promoter. Our hypothesis was that Sost ERT2 Cre would be
expressed only in osteocytes in bone and not in other tissues to
any significant extent. The specificity of this mouse model was
impressive with regards to targeting the mature osteocyte. No
activation was ever observed in muscle, bone marrow, or bone
surface cells. Spontaneous activation of Cre in the absence of
tamoxifen only occurred in a few mature osteocytes in bone. With
tamoxifen injection, this specificity was still mainly targeted to
osteocytes, however, a small amount of off target activity was
observed in a few cells in the retina, heart, brain, and kidney.
Similar to other studies, we did not observe any sclerostin protein
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Fig. 6 Excised muscle and histology from 6 mo male and female Cre− and Cre+ animals. a Image and weight of EDL and SOL muscle from
control Cre− mice and Sost-CreERT2, Cre+, mice at 6 months of age. b Muscle fiber typing by immunohistochemistry and Hematoxylin-Eosin
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expression in these tissues compared to the high expression in
osteocytes.28 Therefore, compared to other Cre models used for
targeting osteocytes, this Cre model has a very high specificity for
the mature osteocyte.
This goal of generating an osteocyte specific targeted Cre was
accomplished but as frequently occurs with transgenic
mouse models, an unexpected phenotype was observed. By X-
ray and micro CT no significant differences were observed in
bone parameters between Cre positive and Cre negative mice.
However, with time, it appeared that the muscles in
these animals were becoming larger as viewed by X-ray
imaging. By 8–10 months, the muscle phenotype was obvious
in Sost ERT2 Cre males and by 12 months in females. Even
though a visual difference in the intact animals or their muscle
appearance was not obvious at 6 months, when excised, the
muscles were larger and abnormalities were evident based on
histology and fiber typing. Functional studies showed that the
muscles for the Cre positive mice were considerably weaker
than controls.
Careful systematic analyses of the Sost ERT2 Cre mice revealed a
pattern compatible with development of partial muscle myopathy.
Healthy muscle has polygonal shaped fibers, relatively small
variation in size, peripheral nuclei, no fiber splitting, and scant
endomyosial collagen.29 Myopathic muscle is characterized by
more central nuclei and they are scattered, atrophic, grouped,
rounded fibers, with significantly more collagen around them
indicating fiber replacement by fibrosis and can show fiber
splitting.29 While many of these characteristics are clear in the Sost
ERT2 Cre positive muscles, they are not atrophic but rather display
possible compensatory hypertrophy, perhaps in adaptation to the
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Fig. 7 Muscle function of 3 and 6 mo male and female Cre− and Cre+ animals. EDL and SOL muscle force vs. stimulation frequency analysis. a
Absolute and specific force for EDL and SOL in 3-month-old male and female Cre– and Cre+ (Sost-CreERT2) mice (n= 6). b Absolute and
specific force for EDL and SOL for 6-month-old male and female Cre– and Cre+ mice (n= 10). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Cre− using
two way ANOVA with Bonferroni post-hoc analysis
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recurring degeneration/regeneration leading to much larger
muscle sizes. Muscle hypertrophy of this type is commonly seen
in dystrophic muscle.30
At the functional level, the reduced muscle specific force
supports the observed findings of remodeling and abnormal
structure in the histological and immunohistochemical analysis.
The larger muscles did not translate into improved muscle
function, and in fact, normalized forces taking into account
muscle size over a wide range of frequencies of stimulation were
reduced in the Sost ERT2 Cre of both genders in both EDL and SOL
muscles, demonstrating that the myopathy-like phenotype
impaired the force generating capacity of the contractile
machinery. This is yet another example that muscle size is not
the most reliable parameter for muscle related studies, but rather
muscle quality, and the need to always match muscle size to
function.31,32 It is interesting that these muscles share some
similarities between regenerating muscle fibers and dystrophic
muscle fibers.33 Our RNA-Seq data is supportive of these ideas.
Dystrophin expression was reduced (approximately 30 fold
decrease in males and 2.5 fold decrease in females) and the
observed phenotype seems to mimic the absence of dystrophin in
Duchenne Muscular Dystrophy. The loss of dystrophin would
invariably make skeletal muscles more fragile and more prone to
damage. This damage may lead to inflammatory responses as well
as to muscle trying to generate new muscle fibers. We observed
significant expression of inflammatory genes which could be the
underlying cause leading to the muscle remodeling and
myopathy. A significant overexpression of myh8, a perinatal
isoform of MHC as well as mhc3, an embryonic isoform, was also
observed. These MHC isoforms normally re-express in regenerat-
ing muscles.
Intriguingly, MUSK (Muscle Associated Receptor Tyrosine
Kinase), a gene that plays essential functions in the maintenance
of the neuromuscular junction is equally down-regulated in both
male and females. Mutations in this gene associate with
congenital Myasthenia Gravis. It is also interesting to note that
there were lower levels of myostatin and FKBP5 (leading to
calcineurin activation) which can lead to muscle growth. One
possibility would be that reduced MUSK and dystrophin expres-
sion lead to remodeling of the muscle and adaptations of growth
to compensate, but these changes ultimately lead to myopathy. It
remains to be determined the molecular mechanisms that induce
these changes and how they interplay together to lead to the
muscle phenotype.
It is also intriguing that in older Sost ERT2 Cre mice reaching
their middle age (10–12 months), there seems to be a natural
protection against fat accumulation, while muscle size still
appears to be macroscopically larger, perhaps a reflection of
lipid and insulin signaling regulatory changes. It might be
interesting to determine if the myopathy persists during aging
and if these larger (but disturbed, myopathic) muscles confer
any protection against sarcopenia and osteopenia.
In summary, a novel inducible Cre model has been generated
for targeting osteocytes, the Sost ERT2 Cre. This model shows high
specificity for osteocytes. However, a low level of spontaneous Cre
activation was seen that increased with age, but only in
osteocytes. A muscle phenotype was also observed that increased
with aging. Care should be exercised when using this model and
the muscle phenotype taken into consideration for any future
studies.
MATERIALS AND METHODS
Generation of mice
In the Cre-ERT system, the Cre recombinase sequence is fused with
a mutated ligand-binding domain from the progesterone or
estrogen receptor (ER).8 This modified ligand-binding domain
becomes localized to the nucleus in the presence of synthetic
steroids, such as tamoxifen or 4-hydroxy-tamoxifen. The Cre-ERT
system allows widespread time-dependent recombination when
the Cre-ERT activity is placed under the control of a strong
promoter. The Cre-ERT2 is 10-fold more sensitive to 4-hydroxy-
tamoxifen than the Cre-ERT model.34
The Bac clone RP24-178J4, 157Kb was used for making the Sost
Cre ERT2. Using standard recombineering techniques, 5’ and 3’
homology arms of about 300pb were prepared such that the
50 bp around the ATG initiation codon will be deleted. The arms
were cloned into the CreERt2-frt-kanamycin-frt cassette that was
put into the plasmid, PL451.35 The plasmid was then electro-
porated into SW105 competent cells, positive clones resistant to
kanamycin-chloramphenicol were selected as described in
Warming et al.35 and protocols supplied by the Neil Copeland
lab. The kanamycin cassette was removed by treatment with
L-arabinose that activates the flip recombinase. Positive clones
were identified by PCR with appropriate primers, and BAC DNA
purified with Marligen Plasmid Midprep kits. The BAC DNA was
then sent to Transgenic Technology Center at UT Southwestern at
Dallas, and injected into C57BL/6 N fertilized eggs. Forty-six tail
DNA preparations were screened by Southern analysis and PCR
and 13 lines were identified that were positive by both Southern
and PCR. 4 of the 13 lines were crossed with the Rosa26-loxP-stop-
loxP-tdTomato and frozen sections analyzed with red
fluorescence.
The founder lines were crossed with Ai9 tdTomato reporter
mice (B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J, reference
007905, The Jackson Laboratory, Bar Harbor, Maine, USA) in
order to study the spatial and temporal recombination in
osteocytes to identify the best line responding with high
recombination after tamoxifen injection. The Ai9 mice harbor a
targeted mutation of the Gt(ROSA)26Sor locus with a loxP-
flanked STOP cassette preventing transcription of a CAG
promoter-driven red fluorescent protein variant (tdTomato),
and are useful as a Cre reporter strain. TdTomato is expressed
following Cre-mediated recombination. Ai9 mice hemizygous for
this Rosa-CAG-LSL-tdTomato-WPRE conditional allele are viable
and fertile. When bred to mice that express Cre recombinase,
the resulting offspring will have the STOP cassette deleted in the
cre-expressing tissue(s); resulting in expression of tdTomato
(Jackson Lab). These mice have been previously used to
characterize numerous Cre models.9
All animal experiments were performed according to an
approved Institutional Animal Care and Use Committee protocol
at the University of Missouri Kansas City (UMKC), conforming to
relevant federal guidelines. The UMKC animal facility is operated
as a specific pathogen-free, AAALAC approved facility. Animal
care and husbandry meet the requirements in the Guide for the
Care and use of Laboratory Animals (8th edition), National
10-month-old male
Cre- Cre-Cre+ Cre+
12-month-old female
Fig. 8 Effects of aging on muscle phenotype of Sost-CreERT2, Cre+,
mice compared to Cre– age matched controls. Representative
images of a 10-month-old male and a 12-month-old female control
Cre– mouse and Sost-CreERT2, Cre+, mice without skin. Black arrow
heads indicate fat tissue around the scapula and hind limb. Red
arrow indicates larger triceps in 10-month-old male mice
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Research Council. Animals are group housed and maintained on
a 12 h light/dark cycle with ad libitum food and water at a
constant temperature of (23 ± 2) °C. Qualified veterinary staff
and/or animal care technicians perform daily health check
inspections.
DNA extraction and genotyping
At ten days of age, (or two days of age when sacrificing pups),
a piece of tail and toe was taken and digested in 500 µL
0.1 mol·L−1 Tris, 5 mmol·L−1 EDTA, 0.2% SDS and 0.2 mol·L−1 NaCl.
Proteinase K was added at a final concentration of 0.2 mg·mL−1.
The samples were incubated at+ 50 °C overnight. The samples
were then vortexed and microfuged at 13 K r·min−1 (Eppendorf
5415D, Hauppauge, NY, USA). DNA was precipitated from the
supernatant using an equal volume of 2-propanol (HPLC
grade, Fisher Scientific, Hanover Park, IL, USA). After centrifugation,
the pellet was washed with 1 mL ethanol (ethanol
200 proof, Decon Laboratories Inc., King of Prussia, PA, USA) and
re-centrifuged for removal of supernatent. The samples were
dried and resuspended in a buffer containing 10mmol·L−1 Tris
and 1mmol·L−1 EDTA. The amount and quality of DNA present in
the buffer was quantitated using a NanoDrop device and software
(NanoDrop 2000 spectrophotometer, Thermo Scientific, Waltham,
MA USA). The DNA was stored at −20 °C.
To genotype, the samples were allowed to thaw at room
temperature. TagMix (Redtaq® Ready Mix PCR, Sigma, St. Louis,
MO, USA) was mixed with primers forward and reverse for Cre. The
sequences are the following Cre-Frd 5’-CCG GGC TGC CAC GAC
CAA GT-3’, Cre-Rvz 5’-GCG CGA GTT GAT AGC TGG CTG GT-3’, Sost-
Fwd 5’-CAC TGC GGG CTC TAC TTC AT-3’, Sost-Rvz 5’-TCT TCA TCC
CGT ACC TTT GG-3’, td tomato WT sequence: 01MR9020: 5’-AAG
GGA GCT GCA GTG GAG TA-3’, 01MR9021: 5’-CCG AAA ATC TGT
GGG AAG TC-3’. The td tomato mutant sequences are 01MR9103;
5’-GGC ATT AAA GCA GCG TAT CC-3’ and 01MR9105: 5’-CTG TTC
CTG TAC GGC ATG G-3’. The primers were ordered from IDT
(Coralville, IO, USA). One microliter of DNA was added to 24 μL of
the mix. PCR was done using PTC-200 (MJ Research, St. Bruno,
Quebec, Canada) and i-cycler (Biorad Laboratories Inc., Hercules,
CA, USA) machines to amplify the DNA sequence of interest. 1.2%
agarose gels (Biorad Laboratories Inc., Hercules, CA, USA) were
used to separate DNA. The genotyping (PCR and gel) was
repeated two times minimum to confirm the genotype for each
mouse.
Tamoxifen injections
Tamoxifen was purchased from Sigma (T5648, Sigma-Aldrich, St.
Louis, MO, USA) and diluted in sterile Corn Oil (C8267, Sigma-
Aldrich, St Louis, MO, USA). The solution was sonicated for
15 min to allow the powder to mix with the oil. 2 mo and 5 mo
old male and female Sost ERT2 Cre+ x td tomato and Sost ERT2
Cre– x td tomato mice were injected i.p. with tamoxifen up to
250–550 mg·kg−1 total dose using a concentration of 20
mg·mL−1 as advised by Jackson Laboratories. The mice received
5 to 6 injections on consecutive days to achieve this total dose.
The dose injected was never more than 100–150 μL per day. Sost
ERT2 Cre+ and Sost ERT2 Cre– control mice were injected with the
same volume of corn oil vehicle.
Epifluorescence microscopy
Before tamoxifen injections, at 2 and 5 months of age, a tail
vertebra was removed under anesthesia (isofluorane) in order to
quantitate the basal amount of Cre recombination in bone
osteocytes. Four weeks later after tamoxifen injections, at 3 and
6 months of age, the animals were sacrificed and bones and soft
tissues were analyzed as described below.
At sacrifice, bones (right femur, and tail vertebrae), soft tissues
and glands (brain, kidney, heart, liver, lung, thymus, muscle,
stomach, skin, small intestine, large intestine, spleen, eye,
gallbladder, urinary bladder, ovaries, testis, uterus, vagina, pancreas,
tongue, trachea, oesophagus, aorta, mammary glands, pituitary
gland, lacrimal gland, salivary glands) were dissected free of fat,
skin, muscle and connective tissue and fixed in 4% PFA for 1 day at
+ 4 °C. The bones were placed in 14% EDTA at room temperature in
the dark for 1 week for decalcification. Organs were washed with 1x
PBS three times for 15min and incubated in 15% sucrose for 4 h,
and sucrose 30% overnight. The next day, organs were embedded
in OCT at −20 °C (optimal cutting temperature, TissueTek, Sakura
Finetek, Torrance, CA, USA). After 1 week in EDTA, bones were
washed and treated with 15% and 30% sucrose, then embedded as
described above. Ten micron thick cryosections of bones and soft
tissues were cut using a cryostat (Leica CM3050S, Buffalo Grove, IL,
USA), with cryotape (Cryofilm type IIc(10), Section Lab Co Ltd.,
Hiroshima, Japan), and placed on positively charged microscope
slides (Superfrost Plus, Shandon, Thermo Scientific, Waltham, MA,
USA). Slides were mounted with DAPI mounting media (Fluor-
oshield™ with DAPI, Sigma, St Louis, MO, USA) and imaged with an
epifluorescence microscope (Eclipse E800, Nikon, Tokyo, Japan),
configured with an Optronics CCD color camera (Optronics, Goleta,
CA) and interfaced with the AnalySIS software (Soft Imaging System
GmbH, Muenster, Germany). For fluorescence imaging a TRITC filter
(excitation 530–550, emission 590–650) and a DAPI filter (excitation
330–380, emission 435–485) were used. Exposures were 125ms for
TdTomato, 125 and 250ms for DAPI at 4x and 20x and 2 and 50ms
for brightfield at 4x and 20x magnifications respectively.
Quantitation of positive osteocytes
Brightfield, DAPI and TdTomato images were taken with 4x and
20x magnifications. The 20x magnification was used to quantitate
osteocyte number. The number of osteocytes stained with DAPI
and the number that were positive for tdTomato fluorescence
were quantitated on 4 images per animal using Image J software
(v1.48 v: Wayne Rasband, National Institutes of Health). The
percentage of positive osteocytes was calculated for each field
and then averaged for each mouse.
Determination of spontaneous Cre activity
To determine spontaneous (non-tamoxifen induced) Cre activity
also termed ‘leakiness’, non-tamoxifen injected animals were
sacrificed at different ages. At day 2, pups were sacrificed by CO2
inhalation and genotyped as described above. The pups were cut
longitudinally, placed in cryomolds with OCT and submersed in
isopentane (AC12647–0010, Fisher scientific, Hanover Park, IL,
USA) in liquid nitrogen, in order to preserve the tissue. The frozen
samples were then stored at −80 °C. Ten micron thick sagittal
cryosections of the pups were prepared using cryotape. Animals at
1, 2, and 5 months were also examined for ‘leakiness’ using the 3rd
to 5th caudal tail vertebrae.
Confocal microscopy
For confocal imaging, sections were imaged on a Leica TCS Sp5 II
confocal microscope (Leica Microsystems, Wetzlar, Germany) in
resonant scanner mode using LAS-AF software version 3.0.0 for
TCS SP8. For imaging tdTomato, laser excitation was 543 nm with
a collection window of 553–650 nm and for imaging DAPI, laser
excitation was 405 nm with a collection window of 410–480 nm.
Imaging was done with a 20x objective (NA 0.7, zoom 1.7, single Z
plane) and a 100x oil objective (NA 1.44 zoom 1.7, 25 Z planes
with a 0.17 µm step size).
Immunostaining for sclerostin
Cryosections (10 µm thick) from eye, lung, heart, and brain were
cut as described above. Endogenous peroxidase was quenched
with 3% hydrogen peroxide in PBS for 10 min in the dark, then
washed with PBS 3 times. Blocking was done with 3% BSA and
10% rabbit serum in PBS for 1 h at room temperature. Then
primary goat anti-mouse sclerostin polyclonal antibody (AF
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1589, R&D, Minneapolis, MN, USA) was diluted at concentrations
of 1:100 and 1:300 in PBS+ 10% rabbit serum and added on the
slides. Goat IgG was used as a negative control. Bone was used
as a positive control (1:50, 1:100, 1:200, 1:500, 1:1 000 tested).
The primary antibody was incubated at+ 4 °C overnight. The
next day, the primary antibody was washed 3 times with PBS
and secondary antibody (rabbit anti-goat) was prepared in PBS
+ 2% rabbit serum and added to the sections for 1 h at room
temperature. The secondary antibody was washed with PBS 3
times and detection was done using the Vector ABC peroxidase
kit (Vector PK-4000, Vector Laboratories, Burlingame, CA),
according to manufacturer’s instructions. The sections were
then incubated 3 min with a substrate containing 0.5 mg·mL−1
DAB (3,3’ diaminobenzidine tetrahydrochloride, Sigma, D5637)
in 50 mmol·L−1 Tris.Cl, distilled water and 30% hydrogen
peroxide (final concentration 0.05%), pH 7.4. Sections were
counterstained with methyl green and the slides were dehy-
drated and mounted in permount. Images were collected on a
Nikon Eclipse E800 microscope (Nikon, Tokyo, Japan) with
brightfield illumination using an Optronics CCD color camera
(Optronics, Goleta, CA) interfaced with the AnalySIS software
(Soft Imaging System GmbH, Muenster, Germany).
Immunostaining for muscle fiber typing
Immunostaining was performed as described by Fry et al.36
Extensor digitorum longus (EDL; primarily glycolytic, fast twitch
muscle) and Soleus (SOL; primarily oxidative, slow twitch
muscle) were dissected then embedded in OCT compound
and rapidly frozen in isopentane in liquid nitrogen. Transverse
cryosections, 14 microns thick, were cut and placed onto glass
slides. The sections were fixed by acetone for 5 min and washed
3 times for 3 min. Blocking was performed using M.O.M. mouse
IgG blocking reagent (MKB-2231, Vector Laboratories) for 1 h,
and the sections were then washed 3 times for 3 min. The
primary antibody for mouse dystrophin (1:150) (VP-D505, Vector
Laboratories) diluted in 2% goat serum/PBS was applied to
sections and incubated overnight at 4 °C in a humidified
chamber. The sections were again washed 3 times for 3 min in
PBS followed by incubation with Goat anti-mouse biotin
secondary antibody (Biotin-SP-AffiniPure goat anti-Mouse IgG
115065–205, Jackson Immunoresearch, West Grove, PA, USA) for
1.5 h at RT, again washing with PBS before application of
fluorophore (AMCA-Streptavidin, Vector Laboratories) diluted
with PBS (1:150) 1 h at RT. This was followed by washing with
PBS, blocking again with M.O.M. for 30 min at RT and washing
with PBS. Then the sections were incubated overnight at 4 °C in
mouse monoclonal antibodies for MHCs diluted in 2% goat
serum/PBS. These were obtained from the Developmental
Studies Hybridoma Bank at the University of Iowa, IA, USA and
included antibodies to Type I fibers (BA.D5 mouse IgG2b, 1:100);
Type IIa (SC.71 mouse IgG1, 1:200); and Type IIb (BF.F3 mouse
IgM, 1:100). The sections were then incubated with secondary
antibodies diluted at 1:250 in 2% goat serum/PBS for 1 h at RT.
These included an Alexa Fluor 647 conjugated goat anti-mouse
IgG2b; an Alexa Fluor 488 conjugated goat anti-mouse IgG1; and
an Alexa Fluor 594 conjugated goat anti-mouse IgM (Life
Technologies, Carlsbad, CA). After washing with PBS, the sections
were post-fixed with methanol for 5 minutes at RT, washed and
coverslip mounted with mounting media (H-1000, Vector Labora-
tories). The samples were imaged as described above with a Nikon
Eclipse E800 epifluorescence microscope using excitation and
emission filters optimized for each fluorophore.
X-ray imaging
On the day of sacrifice, the mice were anesthetized with ketamine/
dex-dormitor (75 mg·kg−1, 0.5 mg·kg−1), injected i.p. (100 μL per
10 g body weight). The mice were then X-rayed using a Faxitron
MX-20 × -ray cabinet (Faxitron, Tucson, AZ, USA) at 2x
magnification and 28 kVP for 10 s in order to obtain X-rays of
the whole body on the ventral and lateral sides.
Microcomputed tomography
Micro CT analysis was performed on the tibia in control wild type
and Sost ERT2 Cre mice at 6-months of age (n= 4 for male and
n= 5 for female). Micro CT scanning was conducted using a
Scanco viva CT40 (Scanco Inc, Basel, Switzerland) at a resolution of
10 µm, 55 kV voltage, 145 µA current, and 200ms integration time
following recommended guidelines.37 Analysis was performed on
tibiae fixed in 70% ethanol. Using our standard approach for adult
bones, a high-resolution scan of the region of interest was
performed. The analysis was performed 2.0 mm to 3.0 mm from
the growth plate for trabecular bone and 1.0 mm to 1.5 mm above
the junction of tibia and fibula for cortical bone. The threshold for
trabecular and cortical bone was set to 270 and 355, respectively.
Three-dimensional analyses were performed to determine the
trabecular bone volume/tissue volume (Tb.BV/TV), trabecular
number (Tb.N), trabecular thickness (Tb.Th), trabecular separation
(Tb.Sp) at the proximal tibia. For cortical bone analysis, bone
volume/tissue volume (Ct.BV/TV), and cortical bone thickness (Ct.
Th) were determined.
Ex vivo skeletal muscle function
These experiments were performed as previously described.31,38
Intact EDL and SOL muscles were dissected from 3 and 6 month
old mice. Muscles were ligated to a force transducer and a fixed
support by the tendons and placed inside Radnotti Chambers
containing oxygenated Ringer’s solution (in mmol·L−1; 142 NaCl, 5
KCl, 1.8 MgCl2, 2.5 CaCl2, 10 HEPES, 10 glucose; pH 7.4) for the
collection of isometric force data using an 8-chamber system.
Experiments were driven by an ADI-PowerLab Software (Colorado
Springs, CO, USA) that is customized for these experiments.
Stimulation voltage (100 V; 500ms trains; 1 ms pulse) was supplied
by a Grass S88X stimulator and contractile measurements were
obtained at room temperature. Muscles were first subjected to the
length-force relationship analysis to determine the optimal length
(Lo) at which maximal force is achieved. Next, muscles were
equilibrated to mimic conditions of normal activity (low duty
cycle). Following 20min equilibration, muscles were stimulated
with frequencies ranging from 1–130 Hz to analyze the force
versus frequency relationship. After contractile measurements,
muscle Lo was measured and muscles were excised at the
myotendonous junctions, blotted dry and weighed for determina-
tion of specific force to account for muscle size through the
following formula:
Force Nð Þ  Lo cmð Þ  1:06 gcm3
 
Muscle MassðgÞ ¼ N=cm
2
RNAseq analysis
Gastrocnemius muscle was isolated from 1 mo old male and 3 mo
old female control wild type and Sost ERT2 Cre mice. Total RNA
was extracted from grastrocnemius muscles using a Fibrous Tissue
RNeasy Midi Kit (Qiagen). Further RNA cleaning was performed
with an RNeasy MinElute Cleanup Kit (Qiagen). Gastrocnemius
muscles from both legs were combined for RNA extraction and
RNA was stored at −80 °C until RNAseq analysis.
Library Preparation and sequencing. The concentration and
quality of total RNA samples were first assessed using Agilent 2100
Bioanalyzer. A RIN (RNA Integrity Number) of five or higher was
required to pass the quality control. Then five hundred nanograms
of RNA per sample was used prepare dual-indexed strand-specific
cDNA library using TruSeq Stranded mRNA Library Prep Kit
(Illumina). The resulting libraries were assessed for its quantity and
size distribution using Qubit and Agilent 2100 Bioanalyzer. Two
hundred picomolar pooled libraries were utilized per flowcell for
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clustering amplification on cBot using HiSeq 3000/4000 PE Cluster
Kit and sequenced with 2 × 75 bp paired-end configuration on
HiSeq4000 (Illumina) using HiSeq 3000/4000 PE SBS Kit. A Phred
quality score (Q score) was used to measure the quality of
sequencing. More than 90% of the sequencing reads reached Q30
(99.9% base call accuracy).
Sequence alignment and gene count. The sequencing data were
first assessed using FastQC (Babraham Bioinformatics, Cambridge,
UK) for quality control. Then all sequenced libraries were mapped
to the mm10 mouse genome using STAR RNA-seq aligner39 with
the following parameter: “--outSAMmapqUnique 60”. The reads
distribution across the genome was assessed using bamutils (from
ngsutils).40 Uniquely mapped sequencing reads were assigned to
mm10 RefSeq genes using featureCounts (from subread)41 with
the following parameters: “-s 2 -p –Q 10”. Quality control of
sequencing and mapping results was summarized using Mul-
tiQC.42 Genes with read count per million (CPM) > 0.5 in more than
2 of the samples were kept. The data were normalized using TMM
(trimmed mean of M values) method. Differential expression
analysis was performed using edgeR.43,44 False discovery rate
(FDR) was computed from p-values using the Benjamini-Hochberg
procedure.
Pathway Analysis. Venn diagrams (http://bioinformatics.psb.
ugent.be/webtools/Venn/) were created using 2 fold up- and
down-regulated genes with FDR < 0.05 compared to wild-type.
The identified shared genes in both genders are listed in
Supplemental Tables 1 and 2. 5 fold up- and down-regulated
genes compared to wild-type were analyzed by Protein ANalysis
THrough Evolutionary Relationships (PANTHER) which is a freely
available, comprehensive classification system (http://www.
pantherdb.org/).45 The PANTHER Overrepresentation Test
(Released 2017–12–05) was used to search the data against the
PANTHER database (PANTHER version 13.1 Released 2018–02–03)
to identify pathways overrepresented in our data when compared
to a reference mouse genome. The analysis is performed by a
Fisher’s Exact Test in combination with a robust False Discovery
Rate (FDR) correction for multiple testing. The pathway classifica-
tion and gene list are provided in the Supplemental Fig. 1b and
Table 3.
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